Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2015 Feb;68(2):93-9.
doi: 10.1136/jclinpath-2014-202571. Epub 2014 Dec 8.

Updated UK Recommendations for HER2 assessment in breast cancer

Emad A Rakha  1 , Sarah E Pinder  2 , John M S Bartlett  3 , Merdol Ibrahim  4 , Jane Starczynski  5 , Pauline J Carder  6 , Elena Provenzano  7 , Andrew Hanby  8 , Sally Hales  9 , Andrew H S Lee  1 , Ian O Ellis  1 ; National Coordinating Committee for Breast Pathology
Collaborators, Affiliations
Free PMC article
Practice Guideline

Updated UK Recommendations for HER2 assessment in breast cancer

Emad A Rakha et al. J Clin Pathol. 2015 Feb.
Free PMC article

Abstract

Human epidermal growth factor receptor 2 (HER2) overexpression is present in approximately 15% of early invasive breast cancers, and is an important predictive and prognostic marker. The substantial benefits achieved with anti-HER2 targeted therapies in patients with HER2-positive breast cancer have emphasised the need for accurate assessment of HER2 status. Current data indicate that HER2 test accuracy improved following previous publication of guidelines and the implementation of an external quality assessment scheme with a decline in false-positive and false-negative rates. This paper provides an update of the guidelines for HER2 testing in the UK. The aim is to further improve the analytical validity and clinical utility of HER2 testing by providing guidelines of test performance parameters, and recommendations on the postanalytical interpretation of test results. HER2 status should be determined in all newly diagnosed and recurrent breast cancers. Testing involves immunohistochemistry with >10% complete strong membrane staining defining a positive status. In situ hybridisation, either fluorescent or bright field chromogenic, is used either upfront or in immunohistochemistry borderline cases to detect the presence of HER2 gene amplification. Situations where repeat HER2 testing is advised are outlined and the impact of genetic heterogeneity is discussed. Strict quality control and external quality assurance of validated assays are essential. Testing laboratories should perform ongoing competency assessment and proficiency tests and ensure the reliability and accuracy of the assay. Pathologists, oncologists and surgeons involved in test interpretation and clinical use should adhere to published guidelines and maintain accurate performance and consistent interpretation of test results.

Keywords: BREAST; BREAST CANCER; BREAST PATHOLOGY.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Recommended HER2 scoring algorithm for immunohistochemistry (IHC) and in situ hybridisation (ISH).
Figure 2
Figure 2
Pathway for HER2 testing.
See this image and copyright information in PMC

References

    1. Slamon DJ, Godolphin W, Jones LA, et al. . Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707–12. - PubMed
    1. Ross JS, Fletcher JA. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol 1999;112(1 Suppl 1):S53–67. - PubMed
    1. Gianni L, Dafni U, Gelber RD, et al. . Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 2011;12:236–44. - PubMed
    1. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. . Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659–72. - PubMed
    1. Gianni L, Eiermann W, Semiglazov V, et al. . Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010;375:377–84. - PubMed

Publication types

MeSH terms